^
    3d
    A Prospective, Single-Arm, Multicenter Clinical Study of Chidamide, Decitabine, PD-1 Monoclonal Antibody Combined with Pegaspargase (Epi-Immuno-Pe) in Elderly/Chemotherapy-Intolerant Patients with Relapsed or Refractory NK/T-Cell Lymphoma (ChiCTR2600117389)
    P=N/A, N=20, Not yet recruiting, The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine
    New trial
    |
    decitabine • Epidaza (chidamide) • Oncaspar liquid (pegaspargase)
    3d
    A prospective, multicenter, cocohort controlled clinical trial on the efficacy and safety of chidamide in maintenance treatment for newly diagnosed high-risk diffuse large B-cell lymphoma (ChiCTR2500112540)
    P=N/A, N=204, Not yet recruiting, The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine
    New trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Epidaza (chidamide)
    3d
    TAS-102 plus Fruquintinib or TAS-102 plus Fruquintinib in combination with Chidamide and Serplulimab as third-line and beyond treatment for metastatic colorectal cancer：A multicenter, randomized, two-arm clinical trial (ChiCTR2500115578)
    P4, N=64, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New P4 trial
    |
    Fruzaqla (fruquintinib) • Epidaza (chidamide) • Lonsurf (trifluridine/tipiracil) • Hetronifly (serplulimab)
    3d
    Clinical Study of Chidamide Combined with Azacitidine for Maintenance Therapy in Adult Acute T Lymphoblastic Leukemia/ T Lymphoblastic Lymphoma After Allogeneic Hematopoietic Stem Cell Transplantation (ChiCTR2500114134)
    P2, N=17, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    azacitidine • Epidaza (chidamide)
    5d
    A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) (clinicaltrials.gov)
    P2, N=36, Recruiting, China Medical University, China
    New P2 trial
    |
    carboplatin • etoposide IV • Epidaza (chidamide)
    7d
    QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=33, Recruiting, Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • albumin-bound paclitaxel • Epidaza (chidamide) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    7d
    Dual epigenetic and nuclear export inhibition by chidamide and selinexor in high grade B-cell lymphomas via survivin and PI3K/AKT inhibition. (PubMed, Clin Epigenetics)
    Our preclinical data highlighted the potential synergistic efficacy of chidamide and selinexor in targeting HGBL-DHL, providing a rationale for further clinical investigation of this therapeutic combination for the treatment of this refractory disease.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • BCL2L1 (BCL2-like 1) • BIRC5 (Baculoviral IAP repeat containing 5) • CCNA2 (Cyclin A2) • ANXA5 (Annexin A5) • HDAC3 (Histone Deacetylase 3)
    |
    Xpovio (selinexor) • Epidaza (chidamide)
    8d
    ENO1 inhibition synergizes with chidamide to induce ferroptosis in PTCL-NOS through metabolic remodeling. (PubMed, Blood Sci)
    Chidamide combined with ENO1 knockdown enhanced the effect of the inhibitor on promoting apoptosis and cell cycle arrest in PTCL-NOS tumor cells. Taken together, the findings suggest that knockdown of ENO1 activates autophagy and promotes ferroptosis, thereby inhibiting PTCL-NOS cell proliferation.
    Journal
    |
    ENO1 (Enolase 1)
    |
    Epidaza (chidamide)
    13d
    S2023-056-01: Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=200, Completed, Chinese PLA General Hospital | Recruiting --> Completed
    Trial completion
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • aclarubicin
    19d
    EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas (clinicaltrials.gov)
    P1/2, N=60, Not yet recruiting, Sun Yat-sen University
    New P1/2 trial
    |
    Epidaza (chidamide) • zeprumetostat (SHR-2554) • golidocitinib (DZD4205)
    24d
    A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P3, N=120, Recruiting, Evopoint Biosciences Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    Epidaza (chidamide) • igermetostat (XNW5004)
    26d
    The Synergistic Anti-Leukemia Effect of Bcl-2 Inhibitor Combined with HDAC Inhibitor by PI3K/AKT/FoxO1 Axis in T-Cell Acute Lymphoblastic Leukemia (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
    The combination of VEN and CDM exerts synergistic anti-leukemia effects by inhibiting cellular proliferation, inducing G0/G1 phase arrest and promoting apoptosis through PI3K/AKT/FoxO1 axis in T-ALL.
    Journal • IO biomarker
    |
    MCL1 (Myeloid cell leukemia 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CDK2 (Cyclin-dependent kinase 2) • CCNE2 (Cyclin E2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    Venclexta (venetoclax) • Epidaza (chidamide)